Articles tagged with Cancer Patients
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A recent study used AI trained on cell-to-cell communication networks to predict drug responsiveness in immunotherapy for cancer. The model demonstrated high accuracy in analyzing samples from 700 patients with four types of cancer, identifying key communication pathways related to responsiveness and resistance.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.
A new study found that lockdown-induced delays in diagnosing melanoma led to over 100,000 years of life lost across Europe and £6.1 billion in costs, mainly due to loss of productivity. The research emphasizes the importance of considering unintended side effects in pandemic planning.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
Researchers identify a promising prognostic biomarker for lung cancer using circulating tumor DNA-based minimal residual disease detection. The study found that this method can effectively guide treatment decisions and predict recurrence risk, potentially modifying the lung cancer treatment paradigm.
A novel three-drug combination of an HDAC inhibitor with two types of immunotherapy achieved a 25% overall response rate and 50% progression-free survival in women with advanced HER2-negative breast cancer. Patients with triple-negative breast cancer had a higher response rate, highlighting the need for further clinical evaluation.
A new study has identified a genetic marker that can predict which patients are likely to respond to immunotherapy in various types of cancer. Tumors with high intragenic rearrangement (IGR) burden, which indicates cryptic structural rearrangements of the genetic code, may respond better to immunotherapy.
A retrospective study found that PRRT was effective in controlling hypoglycemia in 81% of patients with malignant insulinomas, enabling 58% to reduce medication use. The treatment resulted in improved symptom control and reduced potential drug side effects for over 80% of patients.
Researchers developed a novel assay that integrates data from four fusion callers to identify disease-related gene fusions in pediatric tumors with high accuracy and efficiency. The new bioinformatics platform detected fusions, prioritized them, and custom curated downstream processes for consensus fusion calling.
A study of over 3,500 men with prostate cancer found that a plant-based diet significantly improved measures of sexual function, urinary health, and vitality scores. The research suggests that adding more fruits and vegetables to the diet while reducing meat and dairy can have a positive impact on quality of life.
Researchers have created a hydrogel that can be used to heal damaged heart tissue and improve cancer treatments. The gel is made from cellulose nanocrystals derived from wood pulp and has a nanofibrous architecture that replicates the properties of human tissues.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
A study published in The Journal of Urology reports that racial representation matters to Black patients seeking prostate cancer information online. This lack of representation can lead to mistrust and discourage screening among Black men, who have higher rates of prostate cancer compared to White or Hispanic men.
A new tumor spatial mapping tool will help clinicians assess the aggressiveness of cancer and personalize treatment. The tool maps the functional state of oncoproteins onto tumour images, allowing for more accurate diagnosis and informed treatment decisions.
A new study published in The Lancet Oncology demonstrates that the drug enobosarm has anti-tumour effects in oestrogen receptor positive breast cancer patients, providing a novel approach to treatment. The study showed that enobosarm was well tolerated with no significant impact on quality of life.
Researchers identified mechanisms that cause ponatinib to harm the heart and found a promising treatment that could reverse this process. The treatment protects heart cells without diminishing the tumor-fighting efficacy of the drug.
Researchers have developed a new treatment combining immunotherapy with lab-cultivated T-cells from patients' blood, which significantly inhibits triple-negative breast cancer growth and metastasis. The treatment has shown promising outcomes in animal models, but further testing in humans is needed to confirm its effectiveness.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
The study found that only 67.5% of trial publications reported patient-reported outcomes data, with a median time between publication and analysis of 10.5 months. The quality score of the data was low, with a mean score of 11.10 out of 24 points.
Korea University researchers found that perioperative radiotherapy significantly improves survival rates among HCC patients at high risk of recurrence. The study suggests that radiotherapy can reduce recurrence and improve survival in these patients, providing a significant adjuvant treatment option.
A global study has identified evidence-based approaches to prevent breast cancer-related arm lymphoedema (BCRAL) by addressing risk factors and implementing surveillance programs. The research provides a clinical guide for healthcare teams worldwide to adopt a proactive approach in preventing this irreversible complication.
A large study of 432,000 cancer patients who underwent major surgery found an increased rate of venous thromboembolism associated with cancer surgery. The risk persisted for about two to four months postoperatively and varied between cancer types.
A team of researchers found that diffuse anaplasia (DA) subtype of Wilms tumor grows despite high DNA damage and TP53 mutation, leading to resistance to chemotherapy. The study suggests that DA histology emerges through accumulating DNA damage and CNAs, creating selection pressure for TP53 mutations.
Researchers from King's College London developed an AI model to predict brain cancer patient outcomes after radiotherapy. The model showed improved performances when trained on 10,000s of brain MRI scans and can give clinicians accurate predictions with a single routine scan, allowing for early treatment decisions.
Researchers have developed a novel virtual reality-based relaxation therapy that helps cancer patients in palliative care manage symptoms and stress better. The therapy, known as FLOW-VRT-Relaxation, combines standard-of-care relaxation techniques with immersive VR experiences to promote psychological states of flourishing.
Researchers from UPV propose using rCBV as a predictive marker to identify patients with moderately vascularized tumors who benefit most from bevacizumab treatment. This approach enhances treatment efficacy and improves clinical outcomes.
A study found that the 21-gene breast recurrence score test may underestimate chemotherapy benefits for young Black women with estrogen receptor-positive breast cancer. The researchers recommend lowering the test's cutoff point to ensure accurate treatment recommendations for all patients regardless of race or ethnicity.
Researchers have developed an AI-driven test that accurately diagnoses ovarian cancer in women clinically classified as normal, improving detection of early-stage disease. The test uses machine learning and blood metabolite information to assign a probability of disease presence or absence, offering a more clinically informative approach.
A recent study published in Lancet Microbe suggests that immunocompromised patients are at higher risk for COVID infections, but prolonged infections lasting weeks to months are uncommon. The study found that specific conditions, such as B-cell cancers and autoimmune diseases, increase the risk of prolonged infections.
Researchers discovered that cisplatin chemotherapy enhances the immune system's ability to fight bladder cancer by modulating the immune response and damaging DNA in cancer cells. This approach may lead to durable disease control in a subset of patients with metastatic bladder cancer.
Researchers report a case of a patient with EGFR L858R mutant non-small cell lung cancer (NSCLC) who experienced durable disease improvement after empirical treatment with osimertinib. The 'Lazarus effect' refers to the phenomenon where cancer appears to recur after seeming to be in remission.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
Researchers at Penn Medicine analyzed over 400 patients treated with CAR T cell therapy and found only 16 cases of second cancers, mostly solid tumors. A single case of CAR-negative T-cell lymphoma was identified in a patient who developed a secondary lung tumor after treatment.
Researchers found that high levels of FSP1 are associated with relapse after cisplatin treatment in head and neck squamous cell carcinoma. Targeting FSP1 can attenuate tumor stemness and downregulate invasion and metastatic rates, suggesting a potential new approach for treating drug-tolerant persister cancer cells.
A Phase 3 clinical trial found that combining testosterone-blocking drugs prevents cancer spread and extends treatment time in patients with relapsed prostate cancer. The approach is more effective than single-drug treatment in delaying cancer progression.
A new study found that Black patients were more likely to choose active surveillance, while those with a strong desire for a cure or expecting longer life with treatment were less likely. Education and urologist interventions can increase active surveillance adoption among low-risk prostate cancer patients.
A new international trial investigated the safety and efficacy of sabatolimab combined with hypomethylating agents in patients with myelodysplastic neoplasms. The study found manageable side effects, but no significant improvement in response rates or progression-free survival.
This study explores the perspectives of primary care physicians (PCPs) and urologists on active surveillance (AS) care for men with low-risk prostate cancer. Key findings include the importance of patient education and clear communication among care team members to prevent loss to follow-up.
Stacyann Bailey studies how cancer treatment affects bones, hoping to prevent fractures and improve patient outcomes. Up to 50% of patients with metastatic bone disease develop fractures due to treatment, making her work crucial for their quality of life.
Researchers discovered a connection between hepatitis B and C viruses and multiple myeloma, finding that antiviral treatment can improve outcomes. The study suggests that early detection of these infections may lead to better treatment and survival rates for patients with this cancer.
A groundbreaking study identifies FAM3C as a key regulator of breast cancer progression within the tumor microenvironment. The overexpression of FAM3C promotes breast cancer cell survival and metastasis, while its depletion inhibits tumor growth in genetically engineered mouse models.
Researchers identified key characteristics associated with improved CAR T outcomes in large B cell lymphoma, including a B-cell gene expression signature and high CD19 protein expression. Patients who received axicabtagene ciloleucel had better event-free survival compared to those receiving standard therapy.
Sezáry syndrome patients face a vicious circle where cancer and treatment weaken the immune system, allowing bacteria like S. aureus to thrive. Eliminating these bacteria may make cancer cells more susceptible to anti-cancer drugs.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Researchers found a combination treatment involving high doses of radiation and chemotherapy to be safe and effective in treating locally advanced non-small cell lung cancer. The treatment, which includes an adaptive boost plan, showed promising results in improving progression-free survival and reducing toxic side effects.
Researchers discuss clonal hematopoiesis, a condition where cells harbor somatic mutations, and its association with aging, solid tumors, and treatment outcomes. Emerging evidence suggests that CH may play a role in cancer development and survival.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
A new computational model, IRMMa, predicts personalized prognosis for newly diagnosed multiple myeloma patients based on tumor genomics and treatments. The model improves on previous prognostic tools by taking into account individualized risk and distinct subtypes of the disease.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
A study found that patients with breast cancer are more likely to choose distant hospitals for surgery based on factors such as age, ethnicity, and living location. The investigation highlights the potential for healthcare inequalities to worsen if policies do not address these disparities.
A phase III study found that selpercatinib significantly improves cancer progression-free survival in patients with NSCLC and RET gene translocations. The therapy also demonstrated efficacy in treating intracranial lesions, a common challenge in advanced NSCLC.
The Colorado Center for Personalized Medicine has hit a major milestone of returning clinical genetic results to over 30,000 patients, making it a leader in providing personalized patient care. The center is also studying pharmacogenomics and providing results to guide drug selection and dosing.
A new study from Sylvester Comprehensive Cancer Center suggests that prophylactic treatment can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. This approach could eliminate hospital stays and broaden access to immunotherapy treatments for more cancer patients.
A risk model based on routine blood work can identify cancer patients who are more likely to benefit from immune checkpoint inhibitors, increasing treatment efficacy and cost-effectiveness. The study found that patients in the low-risk group had a higher response rate and longer overall survival compared to those in the high-risk group.
A new study found that patients treated at community cancer centers have poorer survival rates compared to those at academic medical centers. The study analyzed data from over 20,000 patients with HPV-related oropharyngeal squamous cell cancers.
Researchers at Brigham and Women's Hospital found nearly 6,000 additional US patients could benefit from immunotherapy treatment due to mismatch repair deficiency. Next-generation sequencing revealed previously missed cases, improving patient outcomes.
Researchers at NUS Yong Loo Lin School of Medicine discovered that certain breast tumour cells sacrifice their own growth to aid other cells in resisting chemotherapy, leading to higher chances of recurrence. Disrupting this cooperation could lead to more effective treatments.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
A study by the University of Sydney and University of Warwick found large gaps in evidence regarding opioid medicines for cancer pain. Non-opioid medicines, including aspirin, may be as effective as opioids for background cancer pain.
A recent review of opioid medicines for cancer pain found surprisingly large gaps in evidence regarding their true benefits. Non-steroidal anti-inflammatory drugs (NSAIDs) may be at least as effective as some opioids for background cancer pain, offering potential alternatives to reduce dependence and waning analgesia over time.